Liu Xiangli, Shang YuFeng, Li Ling, Zhang Xudong, Li Zhaoming, Zhang Mingzhi
Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450000, People's Republic of China.
Cancer Manag Res. 2019 Sep 9;11:8277-8284. doi: 10.2147/CMAR.S215585. eCollection 2019.
Peripheral T-cell lymphoma (PTCL) is often prone to relapse and progression even after formal first-line treatment, and there is no standard regimen for second-line treatment. What is more, the activity of thalidomide against this type of lymphoma is unknown.
The objective of this study was to evaluate the efficacy and safety of GDPT regimen in the treatment of relapsed/refractory peripheral T-cell lymphoma.
In this retrospective study, gemcitabine, cisplatin, prednisone, and thalidomide (GDPT) combination regimen was used as salvage protocol for PTCL that failed in first-line treatment for 29 patients and it was scheduled to give 6 cycles of GDPT therapy in order to better evaluate the efficacy unless there was evidence of disease progression, unacceptable toxicities, or refusal by the patient.
After a total of 106 cycles of GDPT regimen were administered, the result showed that the disease control rate (DCR) achieved 82.8% and overall response rate (ORR) reached 69.0% with 34.5% complete remission (CR) and 34.5% partial remission (PR). The median progression-free survival (PFS) was 10.0 months (95% CI 6.6-13.4) and median OS was 28.0 months (95% CI 19.2-36.8). And the 1-year PFS rate and 1-year OS rate were 43.6% and 64.6%, respectively. Both hematologic and non-hematologic toxicities were moderate and well tolerated. There was no treatment-related death.
Thalidomide in combination with gemcitabine, cisplatin, prednisone regimen is a new promising approach to treating patients with relapse and refractory PTCL.
外周T细胞淋巴瘤（PTCL）即使经过正规的一线治疗也常常易于复发和进展，且二线治疗尚无标准方案。此外，沙利度胺针对这类淋巴瘤的活性尚不清楚。
本研究的目的是评估GDPT方案治疗复发/难治性外周T细胞淋巴瘤的疗效和安全性。
在这项回顾性研究中，吉西他滨、顺铂、泼尼松和沙利度胺（GDPT）联合方案被用作一线治疗失败的PTCL患者的挽救方案，对29例患者采用该方案并计划给予6个周期的GDPT治疗，以便更好地评估疗效，除非有疾病进展、不可接受的毒性或患者拒绝治疗的证据。
在总共给予106个周期的GDPT方案后，结果显示疾病控制率（DCR）达到82.8%，总缓解率（ORR）达到69.0%，其中完全缓解（CR）率为34.5%，部分缓解（PR）率为34.5%。中位无进展生存期（PFS）为10.0个月（95%CI 6.6 - 13.4），中位总生存期（OS）为28.0个月（95%CI 19.2 - 36.8）。1年PFS率和1年OS率分别为43.6%和64.6%。血液学和非血液学毒性均为中度，耐受性良好。无治疗相关死亡。
沙利度胺联合吉西他滨、顺铂、泼尼松方案是治疗复发和难治性PTCL患者的一种新的有前景的方法。
